ArticleJournal of robotic surgery2026
Economic benefits of robotic-assisted ventral hernia repair in India: an analysis of health utility, productivity, and operational gains from the real-world ASPIRE INDIA study.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study estimated the economic benefits of robotic-assisted ventral hernia repair (RVHR) using individual patient data (IPD) from a prospective multicenter study, the ASPIRE INDIA. The 30-day quality-adjusted life-years (QALY) gain was estimated from the EuroQol five-dimension three-level questionnaire scores (EQ-5D-3L), with uncertainty quantified via non-parametric bootstrap resampling. Productivity gains were estimated by wages drawn from a lognormal distribution fitted to Periodic Labour Force Survey (PLFS) 2023-24 data, adjusted to FY2026-27. A joint Monte Carlo (MC) simulation propagated uncertainty across all stochastic inputs. The results were scaled to an annual cohort of 300,000 cases. All assumptions were tested through sensitivity analyses. At 300,000 annual cases, the mean total benefit of RVHR over laparoscopic VHR (LVHR) was INR 2,799 million (95% confidence interval [CI]: INR 846-5,001) at 1x willingness-to-pay (WTP; INR 210,000/QALY) and INR 2,959 million (95% CI: INR 1,010-5,154 million) at 2x WTP. Post-anesthesia care unit (PACU) time saved represented the largest component of estimated economic benefit, which accounted for 65.8% of the total benefit at 1x WTP, followed by patient productivity (19.0%), caregiver productivity (9.5%), and QALY gain (5.7%). These findings identify the principal economic benefit dimensions for RVHR and provide a quantitative basis for structured value discussions at the institutional level regarding robotic-assisted surgery (RAS) adoption that should be considered alongside cost data in future comprehensive economic evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.